Federman & Sherwood
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Antares Pharma, Inc.
October 25, 2017 15:46 ET | Federman & Sherwood
OKLAHOMA CITY, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on October 23, 2017, a class action lawsuit was filed in the United States District Court for the District of...
Neos Therapeutics logo
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
June 19, 2017 21:46 ET | Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Melinta Therapeutics
Melinta Therapeutics Provides Baxdela NDA Update
February 27, 2017 08:00 ET | Melinta Therapeutics
NEW HAVEN, Conn, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company focused on developing novel antibiotics to treat serious bacterial infections, today announced that...
Neos Therapeutics logo
Neos Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
February 16, 2017 07:30 ET | Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics logo
Neos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHD
December 20, 2016 07:30 ET | Neos Therapeutics, Inc
DALLAS/FORT WORTH, Texas, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
FDA Accepts Complete Response Submission Regarding the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
August 14, 2012 08:00 ET | Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed on July 31, 2012 with the U.S. Food and Drug Administration its complete...
Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
August 01, 2012 08:00 ET | Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed yesterday with the U.S. Food and Drug Administration its complete response to...
Hemispherx Biopharma Announces Filing a New Drug Application in Argentina for Ampligen(R) to Treat Chronic Fatigue Syndrome
July 18, 2012 08:00 ET | Hemispherx Biopharma, Inc.
PHILADELPHIA, July 18, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it has submitted a new drug application to ANMAT (Administracion...
Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Ampligen(R) New Drug Application for Chronic Fatigue Syndrome Treatment
July 11, 2012 08:00 ET | Hemispherx Biopharma, Inc.
PHILADELPHIA, July 11, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") recently met with representatives of the U.S. Food and Drug Administration (the...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Signs an Agreement With a Private Hong Kong-Based Company to Develop a Prescription Pharmaceutical Product in the US
March 22, 2012 16:15 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 22, 2012 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it has entered into an agreement to develop for a...